Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT06424834

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06424834
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06424834. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-10 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
Acronym
MVP-ANOCA
Condition
Angina Pectoris
Condition
Microvascular Angina
Condition
Vasospastic Angina
Condition
Myocardial Bridge of Coronary Artery
Intervention (Drug)
Amlodipine
Intervention (Drug)
Nebivolol
Intervention (Drug)
Placebo
Lead sponsor
Stanford University (class: other)
Collaborator
American Heart Association (class: other)

Record details

Record id
cardio:ct-nct06424834
Content hash
318ffceb3ce92d2cff893239218dab7cc4ba9045e6ba781030ea7e0cf5233d80